1. Structure–Activity Relationship Studies of Trisubstituted Isoxazoles as Selective Allosteric Ligands for the Retinoic-Acid-Receptor-Related Orphan Receptor γt
- Author
-
Luc Brunsveld, P.J. Cossar, Christian Ottmann, Femke A. Meijer, Richard G. Doveston, Guido J.M. Oerlemans, Rens M J M de Vries, Bert Klebl, Annet O W M Saris, Bente A. Somsen, Anke Unger, Chemical Biology, Molecular Biosensing for Med. Diagnostics, and ICMS Core
- Subjects
Models, Molecular ,Stereochemistry ,Allosteric regulation ,Ligands ,01 natural sciences ,Article ,Structure-Activity Relationship ,03 medical and health sciences ,chemistry.chemical_compound ,RAR-related orphan receptor gamma ,Drug Discovery ,Humans ,Structure–activity relationship ,Isoxazole ,030304 developmental biology ,Orphan receptor ,0303 health sciences ,Dose-Response Relationship, Drug ,Molecular Structure ,Chemistry ,Isoxazoles ,Nuclear Receptor Subfamily 1, Group F, Member 3 ,3. Good health ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Retinoic acid receptor ,Nuclear receptor ,Molecular Medicine ,Farnesoid X receptor ,Allosteric Site - Abstract
The inhibition of the nuclear receptor retinoic-acid-receptor-related orphan receptor γt (RORγt) is a promising strategy in the treatment of autoimmune diseases. RORγt features an allosteric binding site within its ligand-binding domain that provides an opportunity to overcome drawbacks associated with orthosteric modulators. Recently, trisubstituted isoxazoles were identified as a novel class of allosteric RORγt inverse agonists. This chemotype offers new opportunities for optimization into selective and efficacious allosteric drug-like molecules. Here, we explore the structure-activity relationship profile of the isoxazole series utilizing a combination of structure-based design, X-ray crystallography, and biochemical assays. The initial lead isoxazole (FM26) was optimized, resulting in compounds with a ∼10-fold increase in potency (low nM), significant cellular activity, promising pharmacokinetic properties, and a good selectivity profile over the peroxisome-proliferated-activated receptor γ and the farnesoid X receptor. We envisage that this work will serve as a platform for the accelerated development of isoxazoles and other novel chemotypes for the effective allosteric targeting of RORγt.
- Published
- 2021
- Full Text
- View/download PDF